Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 3

Conditions: Postoperative Nausea and Vomiting; Nausea and Vomiting, Postoperative

Treatments: Drug: casopitant

Study type: Interventional

Funder types: Industry

Identifiers

NCT00334152

NKT102552

Details and patient eligibility

About

This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.

Enrollment: 515 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• History of PONV (postoperative nausea and vomiting) and/or motion sickness.
• Have not smoked for the last 6 months.
• Having certain abdominal, breast, thyroid or shoulder surgery.

Exclusion criteria

• Pregnant or breastfeeding.
• Have certain pre-existing medical conditions or take certain medications.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind